1 Min Read
May 11 (Reuters) - Selecta Biosciences Inc
* Selecta Biosciences commences dosing in Phase 1 clinical trial of nicotine vaccine for smoking cessation and relapse prevention Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.